

6th November 2019

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

Sub.: Compliance Under Regulation 47 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir/Madam,

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the second quarter and half year ended 30th September 2019 published in the following newspapers on 6th November 2019:

1. Mumbai edition of Economic Times and
2. Mumbai edition of Maharashtra Times;
3. Mumbai edition of Lokmat

This is for your information and record.

Yours faithfully,



GAURANG SHAH
AVP - Legal & Company Secretary

Encl.: a/a



ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai - 67,

Phone - +91-22-66061000, Fax- +91-22-66061200

CIN - L23230MH1979PLC022059,

Email - info@ajantapharma.com, Website - www.ajantapharma.com

Extract of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2019

₹ in Crore

Particulars	Quarter ended 30/09/2019	Six month ended 30/09/2019	Quarter ended 30/09/2018	Year ended 31/03/2019
1 Total Income from Operations	642.76	1,254.70	544.11	2,055.37
2 Net Profit for the period before tax (before exceptional and/or extraordinary items)	162.63	314.08	163.84	514.27
3 Net Profit for the period before tax (after exceptional and/or extraordinary items)	161.56	313.01	163.84	514.27
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	116.36	230.99	125.39	386.97
5 Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	116.50	229.83	125.93	383.74
6 Equity Share Capital	17.54	17.54	17.69	17.54
7 Reserve (excluding Revaluation Reserve) as shown in audited balance sheet of 31 March 2019				2,227.67
8 Earnings Per Share (FV of ₹ 2/- each)				
(a) Basic - in ₹	13.34	26.47	14.25	43.97
(b) Diluted - in ₹	13.33	26.47	14.25	43.96

Key information on Standalone Financial Results :

Particulars	Quarter ended 30/09/2019	Six month ended 30/09/2019	Quarter ended 30/09/2018	Year ended 31/03/2019
Total Income from Operations	559.45	1,105.19	465.29	1,772.62
Profit Before Tax	161.90	318.35	141.98	513.05
Profit After Tax	120.70	244.30	104.10	391.76
Total Comprehensive Income	119.53	242.81	103.78	390.48

Notes:

- The above financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 5 November 2019.
- Board of Directors have approved payment of interim dividend of ₹ 13 per equity share of face value of ₹ 2 each.
- The above is an extract of the detailed format of Quarter and Half year Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and half year ended 30 September 2019 alongwith modified opinion in respect of insurance claim recognised by the statutory auditors and explanations by the Company are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

Mumbai, 5 November 2019